Meeting
2020 ASCO Virtual Scientific Program
Prognostic and predictive value of ESR1 mutations in postmenopausal metastatic breast cancer (MBC) patients (pts) resistant to aromatase inhibitors (AI), treated with palbociclib (PAL) in combination with endocrine therapy (ET) or capecitabine (CAP) in the PEARL study.
Authors
Miguel Martin
Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, CIBERONC, Madrid, Spain
Miguel Martin , Christoph Zielinski , Manuel Ruiz-Borrego , Eva Maria Carrasco , Eva Ciruelos , Montserrat Muñoz , Begoña Bermejo , Mireia Margeli Vila , Nicholas C. Turner , Maribel Casas , Antonio Anton , Laura Murillo Jaso , Istvan Lang , Cynthia Huang Bartlett , Maria Koehler , Nuria Martin , Massimo Corsaro , Claire Swift , Bella Nisenbaum , Miguel J. Gil Gil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02028507
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1022)
DOI
10.1200/JCO.2020.38.15_suppl.1022
Abstract #
1022
Poster Bd #
107
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase III study of Palbociclib in combination with Exemestane vs. Capecitabine, in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patients with Resistance to non-steroidal Aromatase inhibitors (NSAI): PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006)
First Author: Miguel Martin
Poster
2023 ASCO Annual Meeting
Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET).
First Author: Virginia G. Kaklamani
Poster
2022 ASCO Annual Meeting
Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
First Author: Senthil Damodaran
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
First Author: Sara M. Tolaney